Thermo Fisher Scientific Inc.
TMO
$599.69
+0.96%
Thermo Fisher Scientific, Inc. is a global leader in serving science, providing analytical instruments, laboratory equipment, diagnostics consumables, and life science reagents to pharmaceutical, biotech, academic, and industrial customers. The company operates through four segments—analytical technologies, specialty diagnostic products, life science solutions, and lab products and services (including CRO)—making it a diversified and essential partner in the healthcare and research ecosystem. As the largest player in the life science tools industry, Thermo Fisher's scale and breadth of offerings create a competitive moat, but the stock is currently under scrutiny as investors weigh its growth recovery against macroeconomic headwinds such as inflation and geopolitical tensions. Recent earnings highlighted operational resilience and a raised long-term outlook, yet the market remains focused on the sustainability of demand across its end markets and the impact of cost pressures on margins.…
TMO
Thermo Fisher Scientific Inc.
$599.69
Investment Opinion: Should I buy TMO Today?
We rate Thermo Fisher as a Buy, given its accelerating revenue growth, strong analyst consensus, and market leadership. The average analyst target of $629.50 implies an 8.5% upside, and the consensus recommendation is a Buy with a mean rating of 1.54. The thesis is that Thermo Fisher's diversified portfolio and operational resilience will drive sustained growth, justifying its premium valuation.
Sign up to view all
TMO 12-Month Price Forecast
The AI model is cautiously bullish on TMO, driven by accelerating revenue growth and a supportive analyst consensus. However, the high valuation and margin pressures temper confidence. The model would upgrade to a more bullish stance if revenue growth exceeds 7% and gross margins stabilize above 41%. Conversely, a downgrade would occur if growth falls below 4% or margins deteriorate further. Overall, the risk-reward is balanced, with a slight tilt toward upside.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on Thermo Fisher Scientific Inc.'s 12-month outlook, with a consensus price target around $631.42 and implied upside of +5.3% versus the current price.
Average Target
$631.42
0 analysts
Implied Upside
+5.3%
vs. current price
Analyst Count
—
covering this stock
Price Range
$520 - $750
Analyst target range
With 26 analysts covering Thermo Fisher, the consensus recommendation is a 'Buy' with a mean rating of 1.54 (where 1 is Strong Buy and 5 is Sell). The average price target is $629.50, implying an 8.5% upside from the current price of $580.02. The distribution of ratings is bullish, with no Sell ratings and a majority of Buy/Outperform ratings, as evidenced by recent actions from Evercore ISI, Wells Fargo, and Barclays maintaining positive stances. The target price range spans from $520 to $750, with the low end representing a 10.3% downside and the high end a 29.3% upside. The wide spread of $230 indicates significant uncertainty about the stock's future performance, likely due to macroeconomic factors and the pace of recovery in end markets. The high target of $750 assumes accelerating growth and margin expansion, while the low target of $520 prices in potential demand softness and cost pressures. Recent rating actions have been predominantly positive, with HSBC downgrading from Buy to Hold in June 2026, but the overall sentiment remains constructive.
Drowning in data?
Find the real signal!
Bulls vs Bears: TMO Investment Factors
Thermo Fisher presents a balanced but slightly bullish case. The bull case is supported by accelerating revenue growth, strong analyst consensus, and market leadership, while the bear case centers on high valuation and margin pressure. The most critical tension is whether the company can sustain its growth recovery and expand margins to justify its premium valuation. If revenue growth continues to accelerate and margins stabilize, the stock could re-rate higher; conversely, any slowdown or margin erosion could trigger a de-rating. Currently, the evidence slightly favors the bulls given the positive earnings momentum and analyst sentiment, but the valuation leaves limited margin of safety.
Bullish
- Accelerating Revenue Growth: Q1 2026 revenue grew 6.2% YoY to $11.01B, up from 4.7% in Q1 2025, indicating a steady recovery across segments. This acceleration, especially in life science solutions and lab products, suggests improving end-market demand.
- Strong Analyst Consensus and Upside: With 26 analysts, the consensus is a Buy (mean rating 1.54) and the average price target of $629.50 implies an 8.5% upside from the current price of $580.02. No Sell ratings and a high target of $750 (29.3% upside) reflect optimism.
- Solid Profitability and Cash Flow: Q1 2026 net income was $1.65B with a net margin of 15.0%, and TTM free cash flow stands at $6.75B. Operating margin of 18.2% remains healthy, supporting continued investment and shareholder returns.
- Market Leadership and Diversification: As the largest life science tools company, Thermo Fisher operates across four segments, reducing reliance on any single market. This diversification provides resilience, as evidenced by its 1-year price gain of 29.2% vs. S&P 500's 21.5%.
Bearish
- High Valuation Premium: Trailing P/E of 32.6x is 48% above the industry average of 22x, and the PEG ratio of 4.5x suggests the stock is overvalued relative to its growth rate. This premium leaves little room for error in earnings execution.
- Margin Compression: Gross margin contracted to 40.7% in Q1 2026 from 41.8% in Q3 2025, reflecting inflationary pressures and product mix shifts. Operating margin also dipped to 18.2% from 18.8% in Q4 2025, indicating cost headwinds.
- Modest Inflation and Geopolitical Risks: Recent news highlighted 'modest inflation' risk amid Middle East tensions, which could pressure margins and disrupt supply chains. Such external factors could dampen the pace of recovery in end markets.
- Potential Overextension Near 52-Week High: At $580.02, the stock trades at 90% of its 52-week range (high $643.99), suggesting limited upside from current levels. The recent sharp run-up from April lows may have priced in near-term positives.
TMO Technical Analysis
Thermo Fisher's stock has exhibited a robust recovery over the past year, with a 1-year price change of +29.2%, significantly outperforming the S&P 500's +21.5% gain. The current price of $580.02 sits at 90% of its 52-week range (low $435.27, high $643.99), indicating the stock is trading near the upper end of its yearly band. This positioning suggests strong momentum and investor confidence, though it also raises the risk of overextension, especially after a sharp run-up from the April lows. The stock's beta of 0.85 implies lower volatility than the market, which may appeal to risk-averse investors seeking stability in a healthcare leader.
Beta
0.85
0.85x market volatility
Max Drawdown
-31.4%
Largest decline past year
52-Week Range
$435-$644
Price range past year
Annual Return
+30.2%
Cumulative gain past year
| Period | TMO Return | S&P 500 |
|---|---|---|
| 1m | +13.8% | +2.4% |
| 3m | +30.6% | +4.7% |
| 6m | +13.8% | +11.7% |
| 1y | +30.2% | +21.3% |
| ytd | +1.2% | +13.4% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
TMO Fundamental Analysis
Thermo Fisher's revenue trajectory is accelerating, with Q1 2026 revenue of $11.01 billion, up 6.2% year-over-year, compared to 4.7% growth in Q1 2025. The sequential improvement from Q4 2025's $12.22 billion (which included a 7.5% YoY increase) indicates a steady recovery across its segments, particularly in life science solutions and lab products. However, the company's gross margin contracted to 40.7% in Q1 2026 from 41.8% in Q3 2025, reflecting inflationary pressures and product mix shifts. Net income for Q1 2026 was $1.65 billion, with a net margin of 15.0%, slightly below the 16.2% achieved in Q4 2025, but still demonstrating solid profitability. The company's operating margin of 18.2% remains healthy, though slightly below the 18.8% seen in Q4 2025, indicating modest cost headwinds.
Quarterly Revenue
$11.0B
2026-03
Revenue YoY Growth
+6.2%
YoY Comparison
Gross Margin
40.7%
Latest Quarter
Free Cash Flow
$6.7B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is TMO Overvalued?
Given Thermo Fisher's positive net income, the trailing P/E ratio of 32.6x is the primary valuation metric, with a forward P/E of 21.1x, implying the market expects significant earnings growth. The gap between trailing and forward multiples suggests an anticipated EPS increase of over 50%, driven by margin expansion and continued revenue growth. Compared to the industry average P/E of 22x (as per valuation data), Thermo Fisher trades at a 48% premium, reflecting its market leadership and superior profitability. However, the PEG ratio of 4.5x indicates that the stock may be overvalued relative to its growth rate, as the market is pricing in optimistic long-term expectations. Historically, the stock's P/E has ranged from 26x to 43x over the past two years, and the current 32.6x sits near the middle of that band, suggesting a balanced valuation relative to its own history.
PE
32.6x
Latest Quarter
vs. Historical
Mid-Range
5-Year PE Range 24x~43x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
21.6x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a debt-to-equity ratio of 0.74, indicating moderate leverage, and interest expenses of $354M in Q1 2026, which could pressure earnings if rates rise. The company's gross margin contracted to 40.7% from 41.8% in Q3 2025, reflecting inflationary pressures, and net margin dipped to 15.0% from 16.2% in Q4 2025. While free cash flow is strong at $6.75B TTM, the high payout ratio of 9.4% for dividends is modest, but the company's reliance on continued growth to justify its premium valuation is a key risk. Revenue concentration in life science solutions (23% of sales) and lab products (remainder) exposes it to cyclicality in research funding and biotech spending.
